Corporate Profile

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia’s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.

Read More

Investment Highlights


Proprietary extended-release technology platform

  • High quantity of active drug delivered versus other polymer-based technologies
  • Patent protection for lead candidate (not including patent term extensions)

Global multi-billion dollar market for lead candidate in osteoarthritis

  • U.S. market for osteoarthritis valued at almost US$2 billion
  • Current global osteoarthritis treatments challenged by poor safety, limited efficacy, and/or limited duration

Pipeline of clinical and non-clinical candidates

  • Lead product candidate for treatment of OA symptoms is widely used corticosteroid with well-established systemic safety record
  • Additional non-clinical candidates in post-surgical pain, anti-infective and veterinary indications, and potentially in oncology

Compelling research results for lead candidate

  • Well tolerated with minimal local and systemic impact
  • Demonstrated immediate and sustained pain relief (WOMAC score)
  • Demonstrated no cartilage damage over 10-month period in non-clinical setting
  • Improvement in WOMAC function

Expected clear regulatory pathway for lead candidate

  • Lower risk approval pathway using U.S. 505(b)(2) application
  • Open IND with the FDA for Phase 2 study
  • Use of proceeds support completion of Phase 2 study
  • Manufacturing at initial commercial launch scale

Experienced management team and board

  • Extensive medical, life science and public company experience
View all news

Latest News

View all presentations

Latest Presentation